blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1664022

EP1664022 - 2-SUBSTITUTED BENZIMIDAZOLE PIPERIDINE ANALOGS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS [Right-click to bookmark this link]
Former [2006/23]2-SUBSTITUTED BENZIMIDAZOLE PIPERIDINES ANALOGS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
[2010/40]
StatusNo opposition filed within time limit
Status updated on  21.04.2012
Database last updated on 02.11.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
Schering Corporation
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530 / US
For all designated states
Pharmacopeia, LLC
c/o Ligand Pharmaceuticals, Inc. 10275 Science Center Drive
San Diego, CA 92121 / US
[2011/24]
Former [2009/38]For all designated states
SCHERING CORPORATION
2000 Galloping Hill Road Kenilworth
New Jersey 07033-0530 / US
For all designated states
Pharmacopeia, LLC
c/o Ligand Pharmaceuticals, Inc. 10275 Science Center Drive
San Diego, CA 92121 / US
Former [2006/23]For all designated states
SCHERING CORPORATION
2000 Galloping Hill Road Kenilworth
New Jersey 07033-0530 / US
For all designated states
Pharmacopeia Drug Discovery, Inc.
3000 Park Boulevard
Cranbury, New Jersey 08512 / US
Inventor(s)01 / BURNETT, Duane, A.
9 Chestnut Avenue
Bernardsville, NJ 07924 / US
02 / WU, Wen-Lian
5 Roney Road
Edison, NJ 08820 / US
03 / SASIKUMAR, Thavalakulamgara, K.
21 Canterbury Lane
Edison, NJ 08820 / US
04 / GREENLEE, William, J.
115 Herrick Avenue
Teaneck, NJ 07666 / US
05 / CAPLEN, Mary, Ann
7 Fern Court
Sayreville, NJ 08872 / US
06 / GUO, Tao
1606 Dahlia Circle
Dayton, NJ 08810 / US
07 / HUNTER, Rachael
27 Chestnut Street
Princeton, NJ 08542 / US
 [2006/23]
Representative(s)Adams, Harvey Vaughan John, et al
Mathys & Squire LLP The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2006/23]Adams, Harvey Vaughan John, et al
Mathys & Squire 120 Holborn
London EC1N 2SQ / GB
Application number, filing date04782252.326.08.2004
[2006/23]
WO2004US27734
Priority number, dateUS20030498876P29.08.2003         Original published format: US 498876 P
[2006/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2005023798
Date:17.03.2005
Language:EN
[2005/11]
Type: A1 Application with search report 
No.:EP1664022
Date:07.06.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 17.03.2005 takes the place of the publication of the European patent application.
[2006/23]
Type: B1 Patent specification 
No.:EP1664022
Date:15.06.2011
Language:EN
[2011/24]
Search report(s)International search report - published on:EP17.03.2005
ClassificationIPC:C07D401/12, C07D401/06, A61K31/454, A61P3/04, A61P3/10
[2006/23]
CPC:
C04B35/632 (EP,US); A61P1/00 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/10 (EP); A61P43/00 (EP);
A61P9/12 (EP); C07D401/06 (EP,US); C07D401/12 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/23]
Extension statesAL29.03.2006
HR29.03.2006
LT29.03.2006
LV29.03.2006
MK29.03.2006
TitleGerman:2-SUBSTITUIERTE BENZIMIDAZOLPIPERIDINANALOGA ALS SELEKTIVE ANTAGONISTEN DES AUF DAS MELANIN-KONZENTRIERENDE HORMON WIRKENDEN REZEPTORS ZUR BEHANDLUNG VON OBESITAS UND VERWANDTEN ERKRANKUNGEN[2010/40]
English:2-SUBSTITUTED BENZIMIDAZOLE PIPERIDINE ANALOGS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS[2010/40]
French:ANALOGUES DE BENZIMIDAZOLE PIPERIDINES 2-SUBSTITUES COMME ANTAGONISTES DU RECEPTEUR DE L'HORMONE DE CONCENTRATION DE LA MELANINE DANS LE TRAITEMENT DE L'OBESITE ET TROUBLES ANALOGUES[2010/40]
Former [2006/23]2-SUBSTITUIERTE BENZIMIDAZOLPIPERIDINANALOGA ALS SELEKTIVE ANTAGONISTEN DES MELANIN CONCENTRATING HORMONE RECEPTORS ZUR BEHANDLUNG VON OBESITAS UND VERWANDTEN ERKRANKUNGEN
Former [2006/23]2-SUBSTITUTED BENZIMIDAZOLE PIPERIDINES ANALOGS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
Former [2006/23]ANALOGUES DE BENZIMIDAZOLE PIPERIDINES 2-SUBSTITUES ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR DE L'HORMONE DE CONCENTRATION DE LA MELANINE DANS LE TRAITEMENT DE L'OBESITE ET TROUBLES ANALOGUES
Entry into regional phase29.03.2006National basic fee paid 
29.03.2006Designation fee(s) paid 
29.03.2006Examination fee paid 
Examination procedure02.03.2005Request for preliminary examination filed
International Preliminary Examining Authority: EP
29.03.2006Examination requested  [2006/23]
15.01.2009Despatch of a communication from the examining division (Time limit: M04)
12.05.2009Reply to a communication from the examining division
28.09.2010Communication of intention to grant the patent
26.01.2011Fee for grant paid
26.01.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.01.2009
Opposition(s)16.03.2012No opposition filed within time limit [2012/21]
Fees paidRenewal fee
07.08.2006Renewal fee patent year 03
03.08.2007Renewal fee patent year 04
27.03.2008Renewal fee patent year 05
07.08.2009Renewal fee patent year 06
06.08.2010Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
DK15.06.2011
EE15.06.2011
FI15.06.2011
HU15.06.2011
IT15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
TR15.06.2011
IE26.08.2011
LU26.08.2011
MC31.08.2011
BG15.09.2011
GR16.09.2011
ES26.09.2011
PT17.10.2011
[2013/45]
Former [2013/44]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
DK15.06.2011
EE15.06.2011
FI15.06.2011
IT15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
TR15.06.2011
IE26.08.2011
LU26.08.2011
MC31.08.2011
BG15.09.2011
GR16.09.2011
ES26.09.2011
PT17.10.2011
Former [2013/29]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
DK15.06.2011
EE15.06.2011
FI15.06.2011
IT15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
IE26.08.2011
LU26.08.2011
MC31.08.2011
BG15.09.2011
GR16.09.2011
ES26.09.2011
PT17.10.2011
Former [2013/25]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
DK15.06.2011
EE15.06.2011
FI15.06.2011
IT15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
IE26.08.2011
LU26.08.2011
MC31.08.2011
GR16.09.2011
ES26.09.2011
PT17.10.2011
Former [2013/22]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
DK15.06.2011
EE15.06.2011
FI15.06.2011
IT15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
IE26.08.2011
MC31.08.2011
GR16.09.2011
ES26.09.2011
PT17.10.2011
Former [2012/35]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
DK15.06.2011
EE15.06.2011
FI15.06.2011
IT15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
IE26.08.2011
MC31.08.2011
GR16.09.2011
PT17.10.2011
Former [2012/31]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
DK15.06.2011
EE15.06.2011
FI15.06.2011
IT15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
MC31.08.2011
GR16.09.2011
PT17.10.2011
Former [2012/23]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
EE15.06.2011
FI15.06.2011
IT15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
MC31.08.2011
GR16.09.2011
PT17.10.2011
Former [2012/18]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
EE15.06.2011
FI15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
MC31.08.2011
GR16.09.2011
PT17.10.2011
Former [2012/11]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
EE15.06.2011
FI15.06.2011
PL15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
GR16.09.2011
PT17.10.2011
Former [2012/10]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
EE15.06.2011
FI15.06.2011
RO15.06.2011
SE15.06.2011
SI15.06.2011
SK15.06.2011
GR16.09.2011
PT17.10.2011
Former [2012/09]AT15.06.2011
BE15.06.2011
CY15.06.2011
CZ15.06.2011
EE15.06.2011
FI15.06.2011
SE15.06.2011
SI15.06.2011
GR16.09.2011
PT17.10.2011
Former [2012/05]AT15.06.2011
BE15.06.2011
CY15.06.2011
FI15.06.2011
SE15.06.2011
SI15.06.2011
GR16.09.2011
Former [2011/52]AT15.06.2011
CY15.06.2011
FI15.06.2011
SE15.06.2011
SI15.06.2011
GR16.09.2011
Former [2011/50]CY15.06.2011
FI15.06.2011
SE15.06.2011
SI15.06.2011
GR16.09.2011
Former [2011/49]CY15.06.2011
FI15.06.2011
SE15.06.2011
GR16.09.2011
Cited inInternational search[AD]US5908830  (SMITH ROY G [US], et al) [AD] 18-35 * claims 1-14 *;
 [A]WO02076947  (SCHERING CORP [US]) [A] 1-35 * page 18 - page 24 * * page 34 - page 75 * * claims 1,13,14,17-30 *;
 [A]WO02081460  (JANSSEN PHARMACEUTICA NV [BE], et al) [A] 1,18-35 * page 16, line 21 - page 17, line 10 * * page 43, compound no. 48 * * claims 1,7-9 *;
 [A]WO02088093  (ABBOTT LAB [US]) [A] 1,32 * abstract *;
 [AP]WO03088908  (BRISTOL MYERS SQUIBB CO [US], et al) [AP] 1-19,30-35* examples 627-646; claims 1,11,25 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.